Search

Displaying results 2141 - 2150 of 4212 in total
  1. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. … [A262102,A262107] Indeed, oncogenic activation, loss of tumor suppressor function, and hypoxia, usually facilitated by cancer cells, are known to upregulate VEGF.

  2. Drug

    Hydrogen peroxide

    go.drugbank.com/drugs/DB11091
    ApprovedInvestigationalVet approved

    As a natural product of metabolism, it readily undergoes decomposition by catalase in normal cells [L2024]. … Hydrogen peroxide is also considered as a generally recognized as safe compound by the FDA [L2024]; it is used as an antimicrobial agent in starch and cheese products, and as an oxidizing and reducing

  3. Drug

    OBE101

    go.drugbank.com/drugs/DB05080
    Experimental

    OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine.

  4. Drug

    Besifovir dipivoxil

    go.drugbank.com/drugs/DB05020
    Investigational

    Besifovir dipivoxil is believed to inhibit viral proliferation by interrupting the replicating machinery of the virus.

  5. Drug

    Norelgestromin

    go.drugbank.com/drugs/DB06713
    ApprovedInvestigational

    [L63816] Combined hormonal contraceptives containing norelgestromin lower the risk of pregnancy primarily by suppressing ovulation.

  6. Drug

    Ethylhexyl methoxycrylene

    go.drugbank.com/drugs/DB11226
    Approved

    Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states [F104].

  7. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368]

  8. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

    go.drugbank.com/drugs/DB10284
    ApprovedInvestigational

    Neisseria meningitidis serogroup B recombinant lp2086 a05 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused by

  9. Drug

    Brilliant blue G

    go.drugbank.com/drugs/DB15594
    Approved

    It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]

  10. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Serplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.